Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Selective adenosine A2A receptor antagonists.

E Ongini¹, A Monopoli, B Cacciari

¹Schering Plough Research Institute, San Raffaele Science Park, Milan, Italy.

Farmaco (Societa Chimica Italiana : 1989)

|May 12, 2001

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Superbasic alkyl-substituted bisphosphazene proton sponges: a new class of deprotonating matrices for negative ion matrix-assisted ionization/laser desorption mass spectrometry of low molecular weight hardly ionizable analytes.

Rapid communications in mass spectrometry : RCM·2017

Same author

Boronic acid chemistry in MALDI MS: a step forward in designing a reactive matrix with molecular recognition capabilities.

Chemical communications (Cambridge, England)·2014

Same author

1,8-bis(dimethylamino)naphthalene/9-aminoacridine: a new binary matrix for lipid fingerprinting of intact bacteria by matrix assisted laser desorption ionization mass spectrometry.

Analytica chimica acta·2013

Same author

Synthetic approaches towards the marine alkyl purines.

Current medicinal chemistry·2013

Same author

Modulation of sleep and waking states by D-1 receptors.

Journal of psychopharmacology (Oxford, England)·2012

Same author

MicroRNA profiling reveals that miR-21, miR486 and miR-214 are upregulated and involved in cell survival in Sézary syndrome.

Cell death & disease·2011

Selective A2A adenosine receptor antagonists, including KW 6002 and SCH 58261, show promise for treating neurodegenerative disorders like Parkinson's disease.

Area of Science:

Pharmacology
Medicinal Chemistry
Neuroscience

Background:

The A2A adenosine receptor is a distinct subtype with significant implications in central nervous system disorders.
Selective antagonists for the A2A receptor have been developed, offering therapeutic potential.

Purpose of the Study:

To review the development and characteristics of selective A2A adenosine receptor antagonists.
To highlight compounds like KW 6002 and SCH 58261 for their potential in treating neurodegenerative diseases.

Main Methods:

Chemical synthesis and modification of xanthine derivatives and non-xanthine heterocycles.
Structure-activity relationship studies to optimize A2A receptor selectivity and pharmacokinetic properties.

Main Results:

Related Experiment Videos

Discovery of xanthine-based antagonists, such as KW 6002, with potent A2A receptor antagonistic properties.
Development of non-xanthine A2A antagonists, including SCH 58261, serving as reference compounds.
Identification of ZM 241385 as a potent A2A antagonist with some A2B receptor interaction.

Conclusions:

Selective A2A adenosine receptor antagonists represent a promising therapeutic strategy for neurodegenerative disorders, particularly Parkinson's disease.
Ongoing research focuses on optimizing these antagonists for improved efficacy and safety profiles.